DNLI - Denali Therapeutics Inc
IEX Last Trade
24.42
0.020 0.082%
Share volume: 763,634
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$24.40
0.02
0.08%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-27 | 2023-05-08 | 2023-08-08 | 2023-11-07 | 2024-02-28 | 2024-05-07 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 1.228 B | 1.460 B | 1.409 B | 1.306 B | 1.237 B | 1.154 B | 1.581 B | 1.503 B | |
| Current Assets | 1.139 B | 1.372 B | 1.325 B | 1.224 B | 1.143 B | 1.064 B | 973.575 M | 928.383 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 32.471 M | 36.104 M | 36.709 M | 33.075 M | 33.628 M | 29.626 M | 36.706 M | 32.339 M | |
| Short Term Investments | 32.471 M | 36.104 M | 36.709 M | 33.075 M | 33.628 M | 29.626 M | 36.706 M | 32.339 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 1.106 B | 1.336 B | 1.288 B | 1.191 B | 1.109 B | 1.035 B | 936.869 M | 896.044 M | |
| Total Non-current Assets | 89.080 M | 87.923 M | 84.182 M | 81.672 M | 93.893 M | 89.780 M | 607.516 M | 574.182 M | |
| Property Plant Equipment | 41.692 M | 44.087 M | 42.117 M | 39.821 M | 48.101 M | 45.589 M | 46.863 M | 48.077 M | |
| Other Assets | 16.117 M | 13.399 M | 14.016 M | 14.434 M | 11.137 M | 18.143 M | 44.621 M | 50.578 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.228 B | 1.460 B | 1.409 B | 1.306 B | 1.237 B | 1.154 B | 1.581 B | 1.503 B | |
| Total liabilities | 416.303 M | 417.812 M | 442.638 M | 118.909 M | 118.446 M | 122.963 M | 125.616 M | 115.514 M | |
| Total current liabilities | 360.670 M | 363.922 M | 391.080 M | 69.357 M | 71.180 M | 77.982 M | 82.582 M | 74.533 M | |
| Accounts Payable | 7.539 M | 2.790 M | 2.215 M | 8.520 M | 1.182 M | 9.483 M | 11.855 M | 13.936 M | |
| Other liabilities | 655.000 K | 858.000 K | 1.012 M | 801.000 K | 379.000 K | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 655.000 K | 858.000 K | 1.012 M | 801.000 K | 379.000 K | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 811.303 M | 1.042 B | 966.706 M | 1.187 B | 1.118 B | 1.031 B | 1.455 B | 1.387 B | |
| Common stock | 123.473 M | 132.967 M | 136.525 M | 137.047 M | 137.645 M | 138.267 M | 149.404 M | 168.831 M | |
| Retained earnings | -872.309 M | -970.987 M | -1.081 B | -897.385 M | -996.738 M | -1.116 B | -1.218 B | -1.317 B |